Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population

Medical Science Monitor

Volumn 18, Issue 8, 2012, Pages

  Buzková, Helena ^a   Pechandová, Kristina ^a   Danzig, Vilém ^b   Vařeka, Tomáš ^b   Perlík, František ^a   Žák, Aleš ^b   Slanař, Ondřej ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

CYP2C9; Fluvastatin; Genetic polymorphism; Hypercholesterolemia; SNP

Indexed keywords

CHOLESTEROL; CYTOCHROME P450 2C9; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CZECH REPUBLIC; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 84866131000     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883272     Document Type: Article

References (26)

1. Zuber RE: Anzenbacherova, and P. Anzenbacher, Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med, 2002; 6(2): 189-98
2. Asberg A, Holdaas H: Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Rev Cardiovasc Ther, 2004; 2(5): 641-52
3. Scripture CD, Pieper JA: Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet, 2001; 40(4): 263-81
4. Neuvonen PJ: Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs, 2010; 11(3): 323-32
5. Toda T et al: Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol, 2009; 105(5): 327-32
6. Scordo MG et al: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol, 2001; 52(4): 447-50
7. Schwarz UI: Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest, 2003; 33(Suppl.2): 23-30
8. Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol, 2001; 52(4): 349-55
9. Kirchheiner J et al: Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther, 2003; 74(2): 186-94
10. Aynacioglu AS et al: Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol, 1999; 48(3): 409-15
11. Dorado P et al: CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol, 2003; 59(3): 221-25
12. Bozina N et al: Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J, 2003; 44(4): 425-28
13. Scordo MG et al: Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res, 2004; 50(2): 195-200
14. Stubbins MJ et al: Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 1996; 6(5): 429-39
15. Yang JQ et al: Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol, 2003; 17(3): 373-76
16. Gaikovitch EA et al: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol, 2003; 59(4): 303-12
17. Yasar U et al: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun, 1999; 254(3): 628-31
18. Buzkova H, Pechandova K, Slanar O, Perlik F: Geneticky polymorfismus cytochromu CYP2C9 v ceske populaci. Klinicka Biochemie a Metabolismus, 2007; 15(36): 102-5
19. Kashani A et al: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation, 2006; 114(25): 2788-97
20. Kivisto KT et al: Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics, 2004; 14(8): 523-25
21. Lindahl A et al: Concentration-and region-dependent intestinal permeability of fluvastatin in the rat. J Pharm Pharmacol, 1998; 50(7): 737-44
22. Bercovich D et al: The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis, 2006; 185(1): 97-107
23. Bogman K et al: HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol, 2001; 132(6): 1183-92
24. Kopplow K et al: Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol, 2005; 68(4): 1031-38
25. Konig J: Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Handb Exp Pharmacol, 2011; (201): 1-28
26. Couvert P et al: Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics, 2008; 9(9): 1217-27